5 Discussion GLP-1RAs have emerged as a paradigm-shifting class of agents, with therapeutic benefits that extend well beyond glycemic control in type 2 diabetes
Some clinical studies have suggested that GLP-1 receptor agonists may have a modest uric acid-lowering effect
However, North Carolina Medicaid does not currently cover GLP-1 medications for weight loss, meaning the expanded coverage population still faces out-of-pocket costs for these treatments
In addition, over the course of time, certain novel bioactive compounds have been explored for their potential as DPP-IV inhibitors through the use of in silico analysis ( Figure 5 )
Since most of a protein's biological functions depend on its three-dimensional (3D) structure, appropriate folding, stability, and interaction between domains must be considered while creating multi-domain recombinant proteins
The American Thyroid Association says that 12 percent of U.S